Introduction
More than half of all child cancer types arise in embryonal cells that have persisted beyond birth, to later undergo changes that result in clinical tumors (Pizzo and Poplack, 2002) . However, the mechanisms of embryonal cancer initiation, promotion and progression are poorly understood (Knudson, 1971; Felsher, 2008) . During normal embryonal neurodevelopment there is initially a proliferation and migration of neural crest cells, although, only 15-40% of post-migratory cells survive to form mature neural tissues (Ferrer et al., 1992; Lossi and Merighi, 2003) . Persistent embryonal cells with tumorigenic capacity must possess both the capacity to resist cell death imposed by trophic factor withdrawal during the final stages of neurodevelopment and undergo secondary changes that characterize later tumor promotion and progression.
Medulloblastoma is postulated to originate from persistent granule neuron precursors (GNPs) in the external granular layer (EGL) during the final stages of cerebellar development (Kadin et al., 1970; Zakhary et al., 2001) . GNPs rapidly proliferate under the paracrine influence of a Sonic Hedgehog (Shh) signal originating from the Purkinje cell layer, before migrating and undergoing terminal differentiation at the internal granular layer (IGL; Corrales et al., 2006) . Cellular responses in the hedgehog pathway are controlled by the ligand Shh acting through the Patched1 (Ptch1) and Smoothened (Smo) membrane proteins. In the absence of Shh, Ptch1 maintains Smo in an inactive state, thus silencing intracellular signaling. With the binding of Shh, Ptch1 inhibition of Smo is released and the signal is transduced. As activity of the pathway is dependent on the Ptch1/Smo interaction, removal of Ptch1 from a cell activates the pathway in a cell-autonomous manner. Once activated, this pathway leads to increased expression of downstream transcription factors, including the Gli family and N-Myc (Murone et al., 1999; Pomeroy et al., 2002; Kenney et al., 2003; Oliver et al., 2003; Wechsler-Reya, 2003) . Failure to switch off growth-promoting signals to GNPs during cerebellar development, such as the Shh pathway, results in medulloblastoma tumorigenesis (Dahmane and Ruiz i Altaba, 1999; Wechsler-Reya and Scott, 1999; Ruiz i Altaba et al., 2004) . Overall, the Shh pathway is proposed to be prevalent in B25% of human cancers (Lum and Beachy, 2004; Fogarty et al., 2005) , with up to 25% of human medulloblastomas having an activated Shh signal (Pomeroy et al., 2002) . Targeted deletions of a single Ptch1 allele in mice produced cerebellar tumors at a median age of 1 year in 14-20% of mice (Goodrich et al., 1997; Wetmore et al., 2000) . The low frequency and long latency of tumorigenesis in these murine models suggest the existence of collaborating oncogenic events.
Studies of N-Myc mRNA expression in Ptch1 þ /À tumors are unclear, with some reporting raised expression (Oliver et al., 2003) , whereas others showing little difference (Lelievre et al., 2008) . Elevated N-Myc expression is present in a significant proportion of human medulloblastoma (Pomeroy et al., 2002; Eberhart et al., 2004) , and is required for Shh-driven medulloblastoma tumorigenesis (Hatton et al., 2006) . Although most studies of N-Myc oncogenesis in human cancer tissues have documented genomic amplification or enhanced transcription, stabilization of the N-Myc degradation pathway has only recently been proposed as another mechanism of deregulation of the N-Myc growth signal in embryonal cancer , as has been reported for Myc-driven tumorigenesis in Burkitt's lymphoma (Bahram et al., 2000) . A better understanding of post-transcriptional Myc (c-Myc) regulation in cancer cells is crucial as elevated expression of the Myc protein is observed in B70% of human tumors, whereas only B20% show amplification or translocation in regions of high transcriptional activity (Nesbit et al., 1999; Arnold and Sears, 2008) . Physiologic studies in normal GNPs show N-Myc expression is important for cell replication, but N-Myc protein degradation is crucial for cell-cycle exit (Kenney et al., 2004; Sjostrom et al., 2005; Benassi et al., 2006) . N-Myc transcription is increased during Shh signaling, with the Cdk1 complex reported to regulate the phosphorylation of serine-62-N-Myc (S62 P -N-Myc, formerly referred to as S54-N-Myc), priming N-Myc for protein degradation (Oliver et al., 2003; Kenney et al., 2004; Sjostrom et al., 2005) before phosphorylation of threonine-58 (T58 P , formerly referred to as T50-N-Myc) by GSK-3b (Sears, 2004; Sjostrom et al., 2005) . On both sites being phosphorylated the prolyl isomerase, Pin1, interacts with Myc to promote dephosphorylation of S62 P by the protein phosphatase 2A (PP2A) complex (Sears, 2004; Yeh et al., 2004) . The Fbxw7 ubiquitin ligase is then able to target T58 P and stimulate proteasomal degradation, a process that may be inhibited if USP28 binds to Fbxw7 (Popov et al., 2007) .
Here we used a Ptch1 þ /À murine model of medulloblastoma, to show that elevated N-Myc expression in GNPs soon after birth enhanced cell replication, and resistance to trophic factor withdrawal at tumor initiation. Loss of Ptch1 expression from the remaining allele and further increases in N-Myc protein expression characterized later tumor progression. We demonstrate that increased N-Myc expression occurred at the protein, but not the transcript, level during tumorigenesis, and, that an activated Shh signal can directly increase Myc protein stability. Despite high levels of S62-and S62/T58-N-Myc phosphorylation in tumor tissue, N-Myc protein expression was markedly increased, and, this correlated with low expression levels of key factors involved in Myc protein degradation.
Results
Selection of N-Myc-expressing focal hyperplasias in the perinatal cerebellum Mice with conditional and tissue-specific hemizygous deletion of the Ptch1 gene (Ptch1 þ /À ) under the control of a Nestin promoter developed cerebellar tumors at a median age of 25.6 ( ± 2.79) weeks in >70% of mice by 52 weeks of age (Supplementary Figure S1) , and were histologically similar to human medulloblastoma (Goodrich et al., 1997; Hahn et al., 2000) . To better define the process of tumor initiation and progression, we undertook a histologic examination of the cerebellum of wild-type (n ¼ 75) and Ptch1 þ /À (n ¼ 83) mice (Figure 1) . We observed the physiologic EGL regression at postnatal day 14 (P14), with the regression complete by P21 (Figures 1a-d) . However, in cerebella from both the wild-type and Ptch1 þ /À mice we observed the continued presence of GNP remnants at the EGL. We have designated these persisting GNPs as focal hyperplasia. A focal hyperplasia consisted of >30 densely packed cells having a high nuclear-to-cytoplasmic ratio by hematoxylin and eosin (H&E) staining (Figure 1d ; Hansford et al., 2004) . Surprisingly, wild-type littermates also demonstrated focal hyperplasia on the surface of the cerebellum at P21, although at a much lower frequency (Figure 1h ). Focal hyperplasias were most often observed as multiple, noncontiguous lesions on the cerebellum of Ptch1 þ /À mice (n ¼ 6.3±1.2 at P21; Figures 1d and h ). Similar histologic findings have been noted in other studies of Ptch1 þ /À mouse models of medulloblastoma (Corcoran and Scott, 2001; Kim et al., 2003; Oliver et al., 2005) . In our studies, focal hyperplasias diminished in frequency from P21, before the later emergence of tumors. We designated collections of >5000 cells as diffuse hyperplasia. These larger collections of malignant, or premalignant, cells were present at a very low frequency from 3 weeks, and persisted after the smaller, but more numerous, focal hyperplasias were no longer evident (Figure 1f) . Thus, many persistent GNPs in focal hyperplasias from Ptch1 þ /À mice at week 3 spontaneously regressed or matured by week 10, implying a process of selection of GNPs that had become competent to progress to diffuse hyperplasia and later tumor formation.
To better understand the role of N-Myc in tumor progression we examined N-Myc and proliferating cell nuclear antigen (PCNA) expression, a proliferative marker, in tissues representing the different stages of tumor initiation and progression (Figure 2a) . Notably, only a small proportion (13%) of focal hyperplasias expressed high levels of N-Myc (Figure 2b ). In contrast, all diffuse hyperplasia lesions and tumors were observed to express high N-Myc diffusely (Figure 2b) . Similarly, the pattern of PCNA expression correlated with N-Myc in focal and diffuse hyperplasias, and tumor tissue (Figures 2b and c) . Together, these observations suggest that one factor allowing selection of persistent GNPs for tumor progression was an acquired increase in N-Myc expression level, which promoted cell proliferation.
EGL regression during development is preceded by increased GNP cell number in the cerebellum of Ptch1 þ /À mice Granule neuron precursors normally undergo a rapid, postnatal expansion in the EGL, which is complete by P21 in mice. We compared histologic features of the EGL in Ptch1 þ /À mice at P7, when the EGL achieves its maximal dimension before regression. We observed a significant increase in the width of the EGL in Ptch1 þ /À mice, in comparison to wild-type mice, for both the whole and outer layer of the EGL (Figures 3a and b) , but not the inner layer, suggesting that Ptch1 þ /À mice have increased numbers of mitotically active GNPs (Wechsler-Reya and Scott, 1999 ). An increased number of cells were also observed migrating through the molecular layer of the cerebellum of Ptch1 þ /À mice (Figure 3c ), indicating that the physiologic process of migration is not inhibited for the majority of the GNPs from the Ptch1 þ /À EGL. The proliferating nature of the GNPs was confirmed when we showed that the number of PCNA-positive GNPs was markedly increased in P7 Ptch1 þ /À mice ( Figure 3d ). Viable GNP cell counts taken after dissociation of the cerebellum at P7 reflected our in vivo observation, that the EGL from Ptch1 þ /À mice demonstrated increased cellularity before regression ( Figure 3bii ). An in situ terminal transferase dUTP nick-end labeling (TUNEL) assay of the EGL of both P7 wild-type and Ptch1 þ /À mice did not show any significant difference for the proportion of apoptotic cells (data not shown). These results show Ptch1 þ /À mice have significantly increased numbers of replicating GNPs in the EGL, which have retained the ability to migrate subsequently to the IGL.
N-Myc expression is required for the viability of postnatal Ptch1 þ /À GNPs As GNPs are produced in excess of requirements, extensive cell death in the developing central nervous system is necessary to shape the structure and systems that permit physiologic functioning. We hypothesized that medulloblastoma tumorigenesis required GNPs from Ptch1 þ /À mice to be dependent on the continued presence of N-Myc for viability on trophic factor withdrawal. First, we established primary cultures of GNPs from P7 wild-type and Ptch1 þ /À mice, in media containing Shh and insulin, an activator of the PI-3 kinase signal that is required for GNP survival (Kenney et al., 2004) . Shh was withdrawn for 24 h and viability was assessed. We observed a significant decrease in the viability of primary wild-type GNPs, following Shh withdrawal, in comparison to its control. In contrast, Ptch1 þ /À mice GNPs showed no significant difference in survival after Shh withdrawal ( Figure 4a ). Increased apoptosis measured by Annexin V binding took place in wild-type GNPs when Shh was withdrawn compared to Ptch1 þ /À GNPs ( Figure 4b ). To identify whether the increased N-Myc expression observed in Ptch1 þ /À GNPs was responsible for increased survival after Shh withdrawal, we transiently transfected scrambled shRNA, or shRNA targeted against N-Myc (shN-Myc) into Ptch1
GNPs. We obtained a 70% decrease in N-Myc expression for shN-Myc-transfected Ptch1 þ /À GNPs, in comparison to scrambled GNPs (Figure 4c ). In response to decreased N-Myc expression, we observed a significantly decreased viability of Ptch1 þ /À GNPs, both with and without Shh (Figure 4d ). To exclude toxicity of the shN-Myc, comparable experiments with pooled N-Myc siRNA were performed with similar results (data not shown). Other trophic factor withdrawal assays, such as PI-3 kinase inhibition or N2 serum withdrawal, resulted in a decreased survival of Ptch1 þ /À GNPs in comparison to wild-type GNPs (Supplementary Figure S2 ). Importantly, the above results indicated that at the time of tumor initiation, N-Myc expression mediated death resistance to trophic factor withdrawal in GNPs from Ptch1 þ /À mice.
N-Myc expression is progressively upregulated by post-translational mechanisms during tumorigenesis in Shh-pathway-activated GNPs We next studied the effect of Ptch1 þ /À on N-Myc transcription and translation. We found no significant difference in N-Myc mRNA expression between P7 wild-type GNPs, P7 Ptch1 þ /À GNPs, and Ptch1 þ /À tumor tissue by either real-time PCR (Figure 5a ) or reverse transcription (RT)-PCR (data not shown). N-Myc mRNA is expressed at high levels in primary GNPs as expected with in vivo Shh stimulation. In contrast, N-Myc protein expression was significantly elevated in Ptch1 þ /À GNPs (>1.4-fold) and further increased in Ptch1 þ /À tumor tissue (>3-fold), compared with wild-type GNPs ( Figure 5b ). As expected, P7 Ptch1 þ /À GNPs expressed lower Ptch1 mRNA and protein levels than P7 wild-type cells, whereas tumor tissue demonstrated complete loss of Ptch1 expression (Figure 5c and d) . We next examined the relative mRNA expression levels of genes involved in the Shh pathway by RT-PCR (Figure 5d ). We observed a significant increase in expression of Gli1, and inhibition of Gli3 mRNA in Ptch1 þ /À tumor tissue, in contrast to P7 GNPs from wild-type and Ptch1 þ /À mice.
Different forms of phosphorylated N-Myc are expressed during tumor initiation and progression
To determine the mechanism for enhanced N-Myc protein stability, we examined the expression of phosphorylated S62-and T58-N-Myc, which regulates the physiologic N-Myc protein degradation process. We observed increased expression of S62 P -N-Myc in both Ptch1 þ /À mouse P7 GNPs (>1.9-fold) and tumor (>5.0-fold), in comparison to wild-type P7 GNPs (Figure 6a) . A similar increase in total N-Myc protein expression was also observed. Unexpectedly, increased expression of the S62 P /T58 P -N-Myc (>2.4-fold) protein form was only seen in tumor, along with decreased expression of T58 P -N-Myc (>3.0-fold) (Figure 6a ). When GNPs and tumor were treated with cycloheximide and actinomycin-D for over 1 h, we determined that N-Myc protein had increased stability in Ptch1 þ /À GNPs in comparison to wild-type and that this stability was significantly enhanced in the tumor (Figure 6b ). An important barrier to analyses of Shh signaling in medulloblastoma tumor cell lines or GNPs in vitro is the loss of Shh responsiveness when these cells are placed in culture (Sasai et al., 2006) . To better understand the mechanism by which the Shh signal regulates N-Myc protein expression, we next used an Shh-inducible in vitro model of the Shh signal in NIH3T3 murine fibroblasts (Shh-Light II cells). We demonstrated that with the addition of Shh to the culture medium these cells readily upregulate Myc and phosphorylated Myc, but not N-Myc, expression (Figure 6c ) by posttranscriptional mechanisms with mRNA expression unchanged (Supplementary Figure S3) . When the cells were treated with cycloheximide over 1 h, in the presence and absence of Shh, we showed that Myc protein stability was increased, following Shh signal activation (Figure 6d ).
Recent evidence suggests that the Cdk1 complex, which contains cyclin B1, is required for S62-N-Myc phosphorylation (Sjostrom et al., 2005) . Furthermore, Ptch1 can bind directly to phosphorylated cyclin B1 preventing its accumulation in the nucleus (Barnes et al., 2005) . We determined that there was an >60-fold increase in cyclin B1 expression in Ptch1 þ /À GNPs, and, a >160-fold increase in tumor tissue, compared to wildtype GNPs (Figure 6d ). We were unable to observe any difference between Ptch1 þ /À GNPs and tumor, in comparison to wild-type GNPs, for either the active or inactive form of GSK-3b (Supplementary Figure S4) , an effector of T58-N-Myc phosphorylation in some settings (Kenney et al., 2004; Knoepfler and Kenney, 2006) . Collectively, these data suggest that those consecutive N-Myc phosphorylation events, which mark N-Myc for degradation, proceed despite increasing N-Myc protein levels during tumor progression in Ptch1 þ /À mice. All experiments were performed on at least three independent occasions. Statistical significance was determined by comparing values for tumor and P7 Ptch1 þ /À mice GNPs with those of P7 wildtype GNPs. The data are presented as mean±s.e.m. (n>4); *Po0.05 and **Po0.01 were considered significant.
The Shh pathway regulates the N-Myc degradation pathway by multiple mechanisms As we observed increased S62 P /T58 P -N-Myc expression only on progression to tumor we assessed the mRNA expression levels of key proteins associated with the Myc degradation pathway in wild-type and Ptch1 þ /À P7 GNPs and tumor tissue. Evidence (Yeh et al., 2004) suggests that the Myc proteolysis effector proteins, Pin1 and the PP2A-B56 complex, direct S62 P dephosphorylation leading to an increase in Myc protein degradation. We observed decreased expression of Pin1, PP2A-B56 isoforms a, b, g and d (data not shown) in tumor (Figure 7a ). Analysis further downstream on Fbxw7 and USP28, both known to influence the stability of T58 P -Myc, identified the two Fbxw7 isoforms a-and b-mRNA to be similarly reduced in tumor tissue only (Figure 7a ). The additional control mechanism for Myc degradation, USP28, which associates with Fbxw7, was not altered. Protein analyses of Fbxw7a and -b did not show reduced expression in tumor in comparison to GNPs (Supplementary Figure S5) . N-Myc proteins are DNA-binding proteins that can activate or repress transcription of effector target genes (Blackwood and Eisenman, 1991) . Thus, we examined transcript expression of well-known N-Myc target genes in wild-type and Ptch1 þ /À P7 GNPs, and tumor tissue (Figure 7b) . None of the nine N-Myc target gene transcript levels was altered by Shh signal activation in the Ptch1 þ /À GNPs. However, we observed significant repression of Activin-A, Id2 and Pax-3, and in contrast, upregulation of Mdm2 and Tert, in medulloblastoma tumor tissue from Ptch1 þ /À mice, compared to GNPs, suggesting these proteins may be involved in the later stages of tumor progression.
Discussion
The final stages of cerebellar development require transient, N-Myc-driven GNP proliferation to provide the necessary population of mature granule neurons for a functional IGL, and, yet continued N-Myc expression in GNPs is a key factor contributing to Shh-driven medulloblastoma tumorigenesis (Hatton et al., 2006) . Our data suggest that in the first week of life GNPs with hemizygous Ptch1 deletion acquire a higher N-Myc protein expression level as an early event, increasing their number and resistance to the physiologic influences that shape terminal cerebellar development. Indeed, only a small proportion of GNP hyperplasias in Ptch1 þ /À cerebella persist beyond the first weeks of life, and this closely correlated with N-Myc expression and the replicative state. Tumor promotion and progression required further increases in N-Myc and, this was provided by loss of Ptch1 expression from the remaining allele, and a reduction in the expression levels of factors regulating the Myc protein degradation pathway. Our data raise important issues regarding the regulation of normal cerebellar development and factors initiating and maintaining medulloblastoma tumorigenesis.
Post-translational modification of Myc proteins, such as phosphorylation, constitutes another level of Myc regulation that may have a significant function in many cellular processes including cell cycle, growth, apoptosis and tumorigenesis. Our data identify an increased S62 P -N-Myc expression at tumor initiation, and later during tumor progression, the acquisition of S62 P /T58 P -N-Myc. This is in contrast to the proposed sequence of phosphorylation steps that characterized N-Myc proteolysis during normal terminal GNP differentiation, as N-Myc expression is shut down (Oliver et al., 2003; Kenney et al., 2004; Sjostrom et al., 2005) . Phosphorylation at S62 stabilized N-Myc, whereas subsequent phosphorylation at T58 was required for N-Myc degradation (Sears et al., 2000; Kenney et al., 2004; Sjostrom et al., 2005) . Consistent with these observations, stabilized Myc through T58 mutation induced oncogenic transformation in human cells (Bahram et al., 2000; Yeh et al., 2004) . Furthermore, in vivo retroviral studies expressing N-Myc mutated at T58 in GNPs significantly enhanced Shh retroviral-induced cerebellar tumor incidence and aggressiveness, when compared to wild-type N-Myc (Browd et al., 2006) . Our data showing high levels of S62/T58 phosphorylation and not T58 phosphorylation at the late tumor stage indicate a failure of N-Myc protein degradation at the S62 dephosphorylation step in the proteolysis pathway (Figure 7c ). Our in vivo findings strongly suggest Pin1 and/or PP2A-B56a as candidate factors permitting increased N-Myc protein stability in tumor. Pin1 and PP2A-B56a proteins have been shown to possess tumor suppressor properties (Arnold and Sears, 2006; Junttila et al., 2007) . Expression of Fbxw7a and -b protein was found to be unchanged in tumor compared to GNPs. It is unclear whether the transcriptional repression of these Myc degradation factors was due to the activated Shh signal, N-Myc alone or simply arose as a general consequence of genomic instability that occurred during the course of medulloblastoma tumorigenesis. In vitro studies on Shh-Light II cells have also indicated that the Shh pathway may have a function when re-activated in adult cancers of inhibiting and stabilizing just not N-Myc, but Myc degradation, thereby permitting increased expression of this oncogene. As most previous analyses of N-Myc expression in human medulloblastoma have assessed only N-Myc mRNA levels and/or amplification, it may also be necessary to reassess N-Myc protein expression levels in human medulloblastoma tissues (Garson et al., 1989; Moriuchi et al., 1996) and its relevance to disease phenotype.
An expanded EGL was observed in this model, similarly in ND2:SmoA1 P14 mice with a constitutively activated Smo gene (Hatton et al., 2008) . It may be that other groups have not previously noted an expanded EGL in Ptch1 þ /À mice with analysis carried out by a total of percentage positive 5-bromo-2-deoxyuridine cells of the EGL. Several groups have previously noted the presence of precancerous lesions in Shh-driven models of medulloblastoma, and that this was N-Myc dependent (Goodrich et al., 1997; Corcoran and Scott, 2001; Kim et al., 2003; Oliver et al., 2005) . Here we have for the first time shown that focal hyperplasias in the perinatal period appeared to be selected for tumor promotion and progression on the basis of N-Myc expression. Moreover, a further incremental increase in N-Myc expression was required to progress from GNP hyperplasia to medulloblastoma. The higher N-Myc expression level, resulting from increased N-Myc protein stability, seen in medulloblastoma tumor cells correlated with effects on some known N-Myc transcriptional target genes: Activin-A, Id2, Tert, MDM2 and Pax3. Little is known of the phenotypic or gene expression profile outcomes in cancer cells expressing different levels of N-Myc, although increasing Myc gene dosage is associated with tumor aggressiveness (Smith et al., 2006) .
In our experiments, tumor cells had complete loss of Ptch1 expression as a collaborating oncogenic event.
It is not clear in other Ptch1
þ /À medulloblastoma models whether Ptch1 was expressed or silenced (Wetmore et al., 2000; Romer et al., 2004; Oliver et al., 2005) , with the use of specific Ptch1 primers critical in the determination of Ptch1 expression (Oliver et al., 2005) . Our studies are consistent with the complete loss of Ptch1 expression being a necessary event for tumor progression. The mechanism for silencing PTCH1 gene expression in sporadic medulloblastoma is still undetermined (Pritchard and Olson, 2008) .
As another layer of regulation, Myc can activate a death program through senescence or apoptosis in certain cell types, in addition to stimulating cell proliferation (Evan et al., 1992; Dang, 1999) . Our work in perinatal GNPs, and previously in perinatal neuroblasts (Hansford et al., 2004) , indicates that certain embryonal cell types are not only susceptible to the Myc proliferative signal, but that Myc expression in these cells conversely inhibits cell death. Consistent with these data Ptch1 þ /À GNPs that have increased phosphorylated S62-N-Myc show increased sensitivity to cell death when PI-3 kinase is inhibited. Elucidation of the mechanism transiently repressing Myc-induced apoptosis in these specialized embryonal cells will be an important step toward understanding those factors that collaborate with N-Myc to initiate embryonal tumorigenesis.
Materials and methods

Mice
Mice with a conditional allele of patched homolog 1 (Ptch1 flox/ þ ) were mated with transgenic mice carrying the Cre recombinase gene under the control of the rat nestin promoter and enhancer (Tronche et al., 1999; Ellis et al., 2003) . Progeny were genotyped by PCR after blinded experiments (Ellis et al., 2003) . Cerebella were dissected into four equal sagittal parts, paraffin-embedded, sectioned and stained with H&E. The average width of the EGL was determined by eight measurements, covering the same areas of the cerebellum for each genotype. The width of the inner and outer EGL was determined by the cell morphology according to Koppel's method (Koppel and Lewis, 1983) . Cell counts from the molecular layer were made from 6 to 8 areas (0.01-0.03 mm 2 ) per section. A total of 157 mice were used in a blinded, weekly, histologic examination of postnatal cerebellum. H&E sections were reviewed under light microscopy by two independent observers and each section scored for the presence of >30-cell focal hyperplasia, diffuse hyperplasia >5000 cells and tumor.
Cell line and protein stability experiments Shh-Light II cells derived from NIH/3T3 cell line were obtained from the ATCC (CRL-2795) and cultured in Dulbecco's modified Eagle's medium with G-418 (0.4 mg/ml), Zeocin (0.15 mg/ml) and 10% fetal calf serum. Shh-Light II cells were plated into 25 cm 2 flasks at 10 4 cells per cm 2 , and stimulated with 40 ng/ml of Shh (R&D Systems, Minneapolis, MN, USA) for 24-36 h. Protein half-life was determined by treating cells with 20 mg/ml of cycloheximide for the designated length of time followed by immunoblot analysis. Primary GNPs and tumor protein half-life was determined by treatment with actinomycin-D (20 mg/ml; Sigma, Australia) and cycloheximide followed by immunoblot analysis.
Isolation of GNPs and tumor cells for culture GNPs were isolated from the cerebellum of P7 mice, and tumor cells from 10-to 45-week-old Ptch1 þ /À mice. Cells were purified by digesting in Hank's balanced salt solution (HBSS; Invitrogen, Mount Waverley, VIC, Australia) containing Lcysteine (0.20 mg/ml) and papain (20 U/ml; Sigma) at 37 1C for 30 min with shaking. Samples were washed, resuspended in HBSS containing 250 U/ml DNase, 4 mM Mg, and were triturated. Cells were then transferred to HBSS containing 100 U/ml DNase and washed. Dissociated cells were washed with complete media: neurobasal media (Invitrogen) supplemented with N 2 (1% v/v; Invitrogen) and sodium pyruvate (1 mM). The cell suspension was centrifuged through a step gradient of 30 and 60% Percoll buffer (GE Healthcare, Piscataway, NJ, USA). Cells obtained from the interface were recognized as purified GNPs and were 98% positive for Math-1 (data not shown). GNPs were cultured in complete media with Shh (20 ng/ml) at 37 1C overnight before cell viability assays. GNPs for RNA and protein extraction were immediately snap-frozen in liquid nitrogen after purification.
Cell viability
Purified GNPs were seeded in a 96-well plate with complete media at 3.0 Â 10 5 cells per cm 2 with Shh (20 ng/ml) or control for 30 h. Cell viability was assessed using the alamarBlue reagent as previously described (Haber et al., 1999) .
Transient transfection
GNPs (2 Â 10 6 cells, 5 mg shRNA; SuperArray, Frederick, MD, USA) were transfected using the Nucleofector and mouse neuron kit (Amaxa, Gaithersburg, MD, USA) as per the manufacturer's protocol. Primary cells transfected with shRNA were assessed at 24-48 h after transfection by RT-PCR and immunoblot. Following transfection with either scrambled shRNA or shRNA targeting N-Myc, the cells were cultured with complete media plus 20 ng/ml of Shh overnight and then separated into two populations, incubated for a further 24 h with and without Shh, and viability was assessed using the alamarBlue assay.
Supplementary material
Materials and methods for Immunohistochemistry, TUNEL, immunoblot, RT-PCR, real-time PCR and Annexin V are given in Supplementary material.
Statistical analysis
Results are expressed as mean values with standard error of the mean (s.e.m). For experiments involving two groups of mice, comparisons were made using one-way analysis of variance. Po0.05 (*) and 0.01 (**) were considered statistically significant.
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